MK-3475 Immunotherapy in Endometrial Carcinoma

Status Completed

Clinical Trial Summary

Due to the high expression of PD-L1 in endometrial cancers as well as in ovarian cancers which are molecularly similar to uterine serous cancers, using pembrolizumab should be beneficial in this patient population. Since the investigators are able to get a pre-treatment research- related endometrial biopsy as well as the surgical specimen post two cycles of pembrolizumab, the investigators will be able to evaluate the mechanism of action of this drug on the endometrial cancer tumor environment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02630823
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Completed
Phase	Phase 1
Start date	February 5, 2016
Completion date	October 3, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05796518` - Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors	N/A
Recruiting	`NCT05489211` - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	Phase 2
Active, not recruiting	`NCT03667716` - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.	Phase 1
Active, not recruiting	`NCT03170960` - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT06463028` - Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer	Phase 2
Recruiting	`NCT06036836` - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)	Phase 2
Terminated	`NCT04586335` - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Phase 1
Completed	`NCT03820024` - MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback	N/A
Active, not recruiting	`NCT05082025` - Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations	Phase 2
Active, not recruiting	`NCT00587886` - Estrogen, Diet, Genetics and Endometrial Cancer
Completed	`NCT05378152` - Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity	N/A
Suspended	`NCT05124743` - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting	`NCT03876860` - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis	N/A
Recruiting	`NCT04569773` - Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
Completed	`NCT04534309` - Behavioral Weight Loss Program for Cancer Survivors in Maryland	N/A
Not yet recruiting	`NCT06073184` - Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium	Phase 2
Not yet recruiting	`NCT05998798` - Revealing Engagement Patterns Among Endometrial Cancer Patients
Not yet recruiting	`NCT06366347` - ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab	Phase 2
Terminated	`NCT02907073` - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter	Phase 1/Phase 2
Completed	`NCT02549989` - Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer	Phase 2